obesity drug news today glp-1 october 21 2025 Ground | Federal regulators approved Eli Lilly's new weight-loss pill, orforglipron, giving patients a second daily oral treatment for What is the pipeline for

One of the most significant breakthroughs in MASLD and MASH targeted therapies is Resmetirom, an Food and Drug Administration (FDA)-approved agent for adults with noncirrhotic MASH with moderate to advanced fibrosis in conjunction to lifestyle therapy

By mimicking the bodys endogenous GLP-1, these drugs suppress appetite, slow gastric emptying, and influence reward mechanisms in the brain

By alleviating chronic systemic inflammation, GLP-1RAs may help prevent the progression of HF and adverse cardiovascular events

Mice treated with GLP-1MK-801 for 14 days exhibited lower plasma insulin levels compared with both vehicle-treated mice and those treated with MK-801 alone (Fig

(July 2016)